Translational Control Mechanisms in Cancer Systems

Translational control has emerged as a central regulator of oncogenesis, dictating which messenger RNAs are preferentially converted into proteins that drive malignancy. At the core of this process is the cap-binding protein eIF4E, which recognises the 5′ mRNA cap and recruits factors required for ribosome assembly. Its activity is finely tuned by eIF4E-binding proteins (4E-BPs) that compete for the same binding surface, and by MNK kinases that phosphorylate eIF4E to modulate its affinity and selectivity. Downstream, mTORC1 integrates growth factor and nutrient cues to phosphorylate 4E-BPs, thereby relieving translational repression and promoting cap-dependent initiation. In many cancers, dysregulation of these nodes amplifies the synthesis of oncogenic drivers such as cyclins, growth factors and survival proteins, while bypassing normal checkpoints. The interplay between canonical cap-dependent translation, alternative internal ribosome entry mechanisms and specialised trans-acting factors underpins tumour heterogeneity and adaptive resistance to therapy. Recent efforts have focused on small-molecule modulators and targeted degradation approaches to restore physiological restraint over protein synthesis.

Research from Nature Portfolio

Fragment-based screening against eIF4E has revealed a previously unrecognised ligand-binding pocket, enabling the structure-guided development of a low-nanomolar tool compound that disrupts both canonical and non-canonical eIF4E:eIF4G interactions. This molecule not only inhibits global translation in cell lysates but also demonstrates selective engagement with eIF4E in intact cells, underscoring the feasibility of targeting “undruggable” initiation factors by combining fragment screening with degrader technology. In diffuse large B-cell lymphoma, MNK1 and MNK2 have been shown to orchestrate a switch between the oncogenic eIF4E1 and its paralogue eIF4E3. Inhibition of MNKs abolishes eIF4E1 phosphorylation and triggers compensatory upregulation of eIF4E3, which exhibits a distinct mRNA selectivity. This work uncovers a dual-isoform regulatory network in which MNKs sustain malignant translation programmes while guarding against uncontrolled eIF4E3-driven protein synthesis.

Translational Control Mechanisms in Cancer Systems publication trend

The graph below shows the total number of articles in translational control mechanisms in cancer systems across all publications each year (not limited to Nature Index journals).

Technical terms

eIF4E: A cap-binding initiation factor that recruits eIF4G and other components to the mRNA 5′ cap, initiating cap-dependent translation.

4E-BP (eIF4E-binding protein): A family of translational repressors that compete with eIF4G for binding to eIF4E, blocking initiation.

MNK (MAP kinase-interacting kinase): A kinase that phosphorylates eIF4E at Ser209, modulating its cap-binding affinity and mRNA selectivity.

mTORC1 (mechanistic target of rapamycin complex 1): A nutrient- and growth factor-sensitive kinase complex that phosphorylates 4E-BPs and S6 kinases to regulate translation.

Cap-dependent translation: The canonical mechanism in which ribosomal recruitment to mRNA is directed by recognition of the 7-methylguanosine cap at the 5′ end.

eIF2·GTP·Met-tRNAi ternary complex: The assembly of eIF2, GTP and initiator methionyl-tRNA required for start codon recognition and ribosome subunit joining.

References

1. Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function. Nature Communications (2024).
2. MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL. Nature Communications (2014).
3. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Oncotarget (2016).
4. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget (2012).
5. Targeting Mnks for Cancer Therapy. Oncotarget (2012).